Veracyte delivered a significant top-line beat in the third quarter of 2026, with total revenue growing 15% year-over-year. While the company surpassed analyst expectations for both revenue and earnings, management narrowed the top end of its full-year 2026 revenue guidance, citing Decipher Prostate volumes that tracked below internal expectations despite double-digit growth.
Key Highlights
- Total revenue reached $151.8 million, exceeding the consensus estimate of $124.82 million.
- Decipher Prostate revenue grew 12% to $92.3 million, though management noted segment volume was lower than anticipated.
- Afirma testing revenue significantly outperformed, jumping 19% year-over-year to $51.5 million.
- The company authorized a $100 million share repurchase program and acquired Convergent Genomics to expand its urology diagnostics portfolio.